Abstract
Objectives: Epilepsy (EP) was a common neurological disorder characterized by excessive abnormal synchronization of neuronal discharges in the brain due to chronic recurrent seizures of multiple etiologies. Recently, a variety of miRNAs were found to be dysregulated, participating in the occurrence and development of various diseases, including EP. This study mainly determines the abnormal expression of miR-378 and miR-575 in EP patients to validate their potential in distinguishing EP from healthy controls.
Methods: Clinical parameters in all participants were recorded. qRT-PCR analysis was applied to determine the expressions of miR-378 and miR-575 in EP patients and healthy volunteers. The student’s t-test and chi-square test was applied to analyze clinical indicators between EP patients and controls. According to the surgical outcome, EP patients were further divided into Engel I~IV EP. The potentials of miR-378 and miR-575 in discriminating EP from healthy participants and predicting surgical prognosis were calculated by receiver operating characteristic (ROC) analysis.
Results: There were no significant differences in age, gender, smoking history, and BMI index between EP patients and healthy controls. miR-378 and miR-575 were significantly declined in Engel I~II and III~IV EP patients in comparison to healthy participants. Moreover, miR-378 and miR-575 displayed high sensitivity, specificity, and accuracy in discriminating EP patients from healthy controls and predicting surgical outcome. Moreover, after surgical treatment, miR-378 and miR-575 levels were increased compared with those at admission, suggesting their potentials in treatment response.
Conclusion: miR-378 and miR-575 could be utilized as novel and non-invasive serum biomarkers in discriminating EP from healthy controls and predicting surgical outcome, shedding new insights on epileptogenesis and EP treatment.
Keywords
Array
Array
Array
References
The published articles will be distributed under the Creative Commons Attribution 4.0 International License (CC BY). It is allowed to copy and redistribute the material in any medium or format, and remix, transform, and build upon it for any purpose, even commercially, as long as appropriate credit is given to the original author(s), a link to the license is provided and it is indicated if changes were made. Users are required to provide full bibliographic description of the original publication (authors, article title, journal title, volume, issue, pages), as well as its DOI code. In electronic publishing, users are also required to link the content with both the original article published in Journal of Medical Biochemistry and the licence used.
Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.